Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.61 |
| ▸ | CNR2 | P34972 | 5/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 7/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333588 | 0.93 | CNR1 (0.52) | CNR1CNR2CSF1RGPR6HTR4 | |
| SCHEMBL4330524 | 0.84 | CNR1 (0.61) | CNR1CNR2CYP1A2KMT2A | |
| SCHEMBL4334587 | 0.84 | CNR2 (0.67) | CNR1CNR2CYP1A2CYP2C19KMT2A | |
| SCHEMBL4331291 | 0.83 | CNR1 (0.61) | CNR1CNR2CYP1A2CYP2C19KMT2A | |
| SCHEMBL4327707 | 0.83 | CNR1 (0.73) | CNR1CNR2CYP1A2CYP2C19KMT2A | |
| SCHEMBL4321808 | 0.83 | CNR1 (0.65) | CNR1CNR2 | |
| SCHEMBL13578118 | 0.82 | CNR1 (0.62) | CNR1CNR2CYP1A2KMT2APKM | |
| SCHEMBL4331219 | 0.81 | CNR1 (0.58) | CNR1CNR2KMT2APKM | |
| SCHEMBL13578117 | 0.80 | CNR1 (0.61) | CNR1CNR2CYP1A2CYP2C19KMT2A | |
| SCHEMBL4341825 | 0.79 | CNR1 (0.63) | CNR1CNR2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR1 2/4885CNR2 1/4885CYP1A2 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.